Biotech

All Articles

AstraZeneca blog posts data on in-house rivals to AbbVie, Pfizer ADCs

.AstraZeneca has shared a very early take a look at the efficiency of its internal antibody-drug con...

iTeos- GSK's TIGIT superstar presents meaningful improvement

.After declaring a stage 3 launch based upon positive midstage outcomes, iTeos and GSK are actually ...

More joint FDA can speed up rare ailment R&ampD: document

.The FDA ought to be actually more available and also collaborative to let loose a surge in approval...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It's an uncommonly occupied Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bicar...

Atea's COVID antiviral stops working to stop hospital stays in stage 3

.Atea Pharmaceuticals' antiviral has actually stopped working one more COVID-19 trial, but the biote...

Neurocrine's quote to spare mental illness possibility neglects

.Neurocrine Biosciences' mental illness program pivot has fallen short. The biotech was unable to re...

Sanofi spends $110M upfront for late-stage radioligand treatment

.Sanofi has created a late entrance to the radioligand celebration, paying for 100 million europeans...

F 2G brings up $100M for 2nd try to receive new antifungal to market

.After F2G's first try to obtain a new course of antifungal to market was actually thwarted due to t...

Moderna targets $1.1 B in R&ampD spending slices, drops 5 systems amidst earnings stress

.Moderna has vowed to reduce R&ampD spending through $1.1 billion by 2027. The selection to retract ...

Sanofi's $80M bank on Pivot dystrophy medicine ends in stage 3 fail

.Just 4 months after Sanofi wager $80 thousand in ahead of time money on Fulcrum Rehabs' losmapimod,...